Stem Cell Therapy Market to Fuel Revenues Through 2020 Lake Shore Gazette – Lake Shore Gazette

Stem cells are most vital cells found in both humans and non-human animals. Stem cells are also known as centerpiece of regenerative medicine. Regenerative medicines have capability to grow new cells and replace damaged and dead cells. Stem cell is the precursors of all cells in the human body. It has the ability to replicate itself and repair and replace other damaged tissues in the human body. In addition, stem cell based therapies are used in the treatment of several chronic diseases such as cancer and blood disorders.

To remain ahead of your competitors, request for a sample here@

https://www.persistencemarketresearch.com/samples/3253

The global stem cell therapy market is categorized based on various modes of treatment and by therapeutic applications. The treatment segment is further sub-segmented into autologous stem cell therapy and allogeneic stem cell therapy. The application segment includes metabolic diseases, eye diseases, immune system diseases, musculoskeletal disorders, central nervous system disorders, cardiovascular diseases and wounds and injuries.

In terms of geographic, North America dominates the global stem cell therapy market due to increased research activities on stem cells. The U.S. represents the largest market for stem cell therapy followed by Canada in North America. However, Asia is expected to show high growth rates in the next five years in global stem cell therapy market due to increasing population. In addition, increasing government support by providing funds is also supporting in growth of the stem cell therapy market in Asia. China and India are expected to be the fastest growing stem cell therapy markets in Asia.

To receive extensive list of important regions, Request Methodology here @

https://www.persistencemarketresearch.com/methodology/3253

In recent time, increasing prevalence of chronic diseases and increasing funds from government organizations are some of the major drivers for global stem cell therapy market. In addition, rising awareness about stem cell therapies and increasing focus on stem cell research are also supporting in growth of global stem cell therapy market. However, less developed research infrastructure for stem cell therapies and ethical issues related to embryonic stem cells are some of the major restraints for global stem cell therapy market. In addition, complexity related with the preservation of stem cell also obstructs the growth of global stem cell therapy market.

Some of the major companies operating in the global stem cell therapy market are Mesoblast Ltd., Celgene Corporation, Aastrom Biosciences, Inc. and StemCells, Inc.

You Can Request for TOC Here @ https://www.persistencemarketresearch.com/toc/3253

Explore Extensive Coverage of PMR`s

Life Sciences & Transformational HealthLandscape

About us:

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics andmarket research methodologyto help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Our client success stories feature a range of clients from Fortune 500 companies to fast-growing startups. PMRs collaborative environment is committed to building industry-specific solutions by transforming data from multiple streams into a strategic asset.

Contact us:

Naved Beg Persistence Market Research Address 305 Broadway, 7th Floor, New York City, NY 10007 United States U.S. Ph. +1-646-568-7751 USA-Canada Toll-free +1 800-961-0353 Salessales@persistencemarketresearch.com Websitehttps://www.persistencemarketresearch.com

See original here:
Stem Cell Therapy Market to Fuel Revenues Through 2020 Lake Shore Gazette - Lake Shore Gazette

ERC-funded postdoctoral position at the Institut of Human Genetics, – Nature.com

The University Hospital Heidelberg is one of the major healthcare centers in Germany. Our objective is the development of innovative diagnostics and therapies as well as their quick implementation for the patient. With about 10,700 employees in more than 50 specialized clinical departments with almost 2,000 beds, about 80,000 patients in part-time and full-time inpatient treatment as well as 1,000,000 patients in ambulant treatment are medicated each year.

JobID: P0025V280

Location: Institut of Human Genetics, INF 366, 69120 Heidelberg Contract: 2 years with extension possibilities, begin as soon as possible Salary: Competitive, subject to skills and experience

The newly created Nephrogenetics unit headed by Matias Simons is looking for an enthusiastic postdoc to join our research group at the Institute of Human Genetics of the University Hospital Heidelberg. The general interest of the lab is in the molecular mechanisms underlying hereditary kidney and metabolic diseases. Most of these diseases are caused by single-gene defects and thereby offer unique opportunities to decipher fundamental regulatory pathways of human physiology and to develop targeted diagnostic and therapeutic options. Recent publications include Marchesin et al, Cell Rep 2020; Bedin et al, J Clin Invest 2019; Goncalves et al, PloS Genetics 2018; Simons, JASN 2018; Rujano et al, J Exp Med 2017; Trepiccione et al, JASN 2016; Gleixner et al, Cell Rep 2014. We combine human genetics with several experimental approaches, including fly and mouse genetics, cell culture, microscopy and biochemistry. For more info on the lab see http://www.simons-lab.de.

We offer an exciting project aimed at exploring the role of random monoallelic expression in renal development and homeostasis. For this project, we invite applications from individuals with a solid background in molecular cell biology. Prior experience with stem cells (e.g. mouse ESCs), organoids, single cell RNA-seq, epigenetics and kidney research is an advantage but not a prerequisite. The projects will be carried out in a stimulating work environment with scientific collaborations within the institute, across the Heidelberg life science community (e.g. EMBL, DKFZ) and worldwide.

The successful applicant will have good communication and organisational skills and a PhD in a relevant area (or be in the final stages of completion). We also invite applications from research-oriented MDs. Candidates are expected to be highly motivated and to work independently with a strong work ethic. As we are an international lab, profictiency in English language is a requirement. Applications including a cover letter, a detailed CV including a publication list and contacts of up to three referees should be sent as soon as possible to matias.simons@med.uni-heidelberg.de

The University Hospital Heidelberg offers:

http://www.klinikum.uni-heidelberg.de/karriere

We stand for equal opportunities. People with disabilities are given priority with the same suitability. The university hospital aims at a general increase in the proportion of women in all areas and positions where women are underrepresented. Qualified women are therefore particularly encouraged to apply.

Read the original:
ERC-funded postdoctoral position at the Institut of Human Genetics, - Nature.com

Omeros Corporation : – Expert Panel Points to Central Role of Endothelial Injury and Lectin Pathway Activation in Critically Ill COVID-19 Patients -…

SEATTLE - Omeros Corporation (Nasdaq: OMER) today announced that the Demy-Colton Virtual Salon Series featured an expert discussion of developments in the treatment of severe COVID-19.

The panel session, entitled Lessons from Bergamo: Discoveries in Treating Critically-ill COVID-19 Patients, was held on September 2, 2020 and included international experts in hematology, oncology and complement science. The panel was moderated by Sara Jane Demy, founder and chief executive officer of Demy-Colton. A replay of the panel can be viewed here (free registration required).

The panel discussed the emerging evidence that endothelial injury and the activation of the lectin pathway of complement are central drivers of the acute respiratory distress syndrome (ARDS) and thrombosis seen in critically ill COVID-19 patients. Narsoplimab, Omeros' investigational human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2), the key effector of the lectin pathway of complement, was identified as a potentially highly effective therapy to treat critically ill COVID-19 patients.

Omeros previously announced positive results from the treatment with narsoplimab of six critically ill COVID-19 patients under a compassionate use protocol. All patients initially required mechanical ventilation and, following treatment with narsoplimab, all recovered, survived and were discharged from the hospital.

About Narsoplimab

Narsoplimab, also known as 'OMS721,' is an investigational human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2), a novel pro-inflammatory protein target and the effector enzyme of the lectin pathway of complement. Importantly, inhibition of MASP-2 does not appear to interfere with the antibody-dependent classical complement activation pathway, which is a critical component of the acquired immune response to infection. Omeros controls the worldwide rights to MASP-2 and all therapeutics targeting MASP-2.

Phase 3 clinical programs are in progress for narsoplimab in hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA), in immunoglobulin A (IgA) nephropathy, and in atypical hemolytic uremic syndrome (aHUS). The FDA has granted narsoplimab breakthrough therapy designations for HSCT-TMA and for IgA nephropathy; orphan drug status for the prevention (inhibition) of complement-mediated thrombotic microangiopathies, for the treatment of HSCT-TMA and for the treatment of IgA nephropathy and fast track designation for the treatment of patients with aHUS. The European Medicines Agency has granted orphan drug designation to narsoplimab for treatment in HSCT and for treatment of primary IgA nephropathy.

About Omeros Corporation

Omeros is a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system and immune-related diseases, including cancers. In addition to its commercial product OMIDRIA (phenylephrine and ketorolac intraocular solution) 1%/0.3%, Omeros has multiple late-stage clinical development programs focused on complement-mediated disorders, including COVID-19, and substance abuse. A rolling biologics license application for narsoplimab, the company's lead MASP-2 inhibitor, in hematopoietic stem cell transplant-associated thrombotic microangiopathy is being completed for submission to the U.S. FDA. Omeros also has a diverse group of preclinical programs including GPR174, a novel target in immuno-oncology that modulates a new cancer immunity axis recently discovered by Omeros. Small-molecule inhibitors of GPR174 are part of Omeros' proprietary G protein-coupled receptor (GPCR) platform through which it controls 54 new GPCR drug targets and their corresponding compounds. The company also exclusively possesses a novel antibody-generating platform.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which are subject to the 'safe harbor' created by those sections for such statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as 'anticipate,' 'believe,' 'can,' 'could,' 'estimate,' 'expect,' 'goal,' 'intend,' 'likely', 'look forward to,' 'may,' 'on track,' 'plan,' 'potential,' 'predict,' 'project,' 'prospects,' 'scheduled,' 'should,' 'slated,' 'targeting,' 'will,' 'would' and similar expressions and variations thereof. Forward-looking statements, including statements regarding anticipated regulatory submissions, the timing and results of ongoing or anticipated clinical trials, and the therapeutic application of Omeros' investigational product, are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. Omeros' actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, availability and timing of data from clinical trials and the results of such trials, unproven preclinical and clinical development activities, regulatory oversight, intellectual property claims, competitive developments, litigation, and the risks, uncertainties and other factors described under the heading 'Risk Factors' in the company's Annual Report on Form 10-K for the year ended December 31, 2019, filed with the Securities and Exchange Commission (SEC) on March 2, 2020, as supplemented by its Quarterly Report on Form 10-Q filed with the SEC on August 10, 2020 and subsequent filings with the SEC. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and the company assumes no obligation to update these forward-looking statements, whether as a result of any new information, future events or otherwise, except as required by applicable law.

Contact:

Jennifer Cook Williams

Tel: 360.668.3701

Email: jennifer@cwcomm.org

(C) 2020 Electronic News Publishing, source ENP Newswire

Continue reading here:
Omeros Corporation : - Expert Panel Points to Central Role of Endothelial Injury and Lectin Pathway Activation in Critically Ill COVID-19 Patients -...

Animal Stem Cell Therapy Market 2020 with Top Countries Data : Market Size, Growth, Segments, Revenue, Top Manufacturers and Forecast to 2024 -…

Animacel

Scope of the Animal Stem Cell Therapy Market Report:The classification of animal stem cell therapy includes dogs, horses and others. And the proportion of dogs in 2020 is about 50.42%, and the proportion is in increasing trend from 2013 to 2020.North America is the largest consumption region of animal stem cell therapy, with a consumption market share nearly 58.63% in 2020. Japan is the second largest supplier of animal stem cell therapy, enjoying production market share nearly 15.17% in 2020.

The worldwide market for Animal Stem Cell Therapy is expected to grow at a CAGR of roughly 38.3% over the next five years, will reach 110 million US$ in 2024, from 16 million US$ in 2019, According to a New Research study.

This report focuses on the Animal Stem Cell Therapy in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.

Get a Sample Copy of the Report:Animal Stem Cell Therapy Market 2020

Report further studies the market development status and future Animal Stem Cell Therapy Market trend across the world. Also, it splits Animal Stem Cell Therapy market Segmentation by Type and by Applications to fully and deeply research and reveal market profile and prospects.

Major Classifications are as follows:

Geographically,this report is segmented into severalkey regions, with sales, revenue, market share and growth Rate of Animal Stem Cell Therapy in these regions, from 2014 to 2024, covering

This Animal Stem Cell Therapy Market Research/Analysis Report Contains Answers to your following Questions

Inquire more and share questions if any before the purchase on this report at https://www.360researchreports.com/enquiry/pre-order-enquiry/13837427

Major Points from Table of Contents:

1. Market Overview 1.1 Animal Stem Cell Therapy Introduction 1.2 Market Analysis by Type 1.3 Market Analysis by Applications 1.4 Market Dynamics 1.4.1 Market Opportunities 1.4.2 Market Risk 1.4.3 Market Driving Force

2.Manufacturers Profiles

2.4.1 Business Overview 2.4.2 Animal Stem Cell Therapy Type and Applications 2.4.2.1 Product A 2.4.2.2 Product B

3.Global Animal Stem Cell Therapy Sales, Revenue, Market Share and Competition By Manufacturer (2019-2020)

3.1 Global Animal Stem Cell Therapy Sales and Market Share by Manufacturer (2019-2020) 3.2 Global Animal Stem Cell Therapy Revenue and Market Share by Manufacturer (2019-2020) 3.3 Market Concentration Rates 3.3.1 Top 3 Animal Stem Cell Therapy Manufacturer Market Share in 2020 3.3.2 Top 6 Animal Stem Cell Therapy Manufacturer Market Share in 2020 3.4 Market Competition Trend

4.Global Animal Stem Cell Therapy Market Analysis by Regions

4.1 Global Animal Stem Cell Therapy Sales, Revenue and Market Share by Regions 4.1.1 Global Animal Stem Cell Therapy Sales and Market Share by Regions (2014-2019) 4.1.2 Global Animal Stem Cell Therapy Revenue and Market Share by Regions (2014-2019) 4.2 North America Animal Stem Cell Therapy Sales and Growth Rate (2014-2019) 4.3 Europe Animal Stem Cell Therapy Sales and Growth Rate (2014-2019) 4.4 Asia-Pacific Animal Stem Cell Therapy Sales and Growth Rate (2014-2019) 4.6 South America Animal Stem Cell Therapy Sales and Growth Rate (2014-2019) 4.6 Middle East and Africa Animal Stem Cell Therapy Sales and Growth Rate (2014-2019)

Get a Sample PDF of report:Animal Stem Cell Therapy Market 2020

5.Animal Stem Cell Therapy Market Forecast (2020-2024) 5.1 Global Animal Stem Cell Therapy Sales, Revenue and Growth Rate (2020-2024) 5.2 Animal Stem Cell Therapy Market Forecast by Regions (2020-2024) 5.3 Animal Stem Cell Therapy Market Forecast by Type (2020-2024) 5.3.1 Global Animal Stem Cell Therapy Sales Forecast by Type (2020-2024) 5.3.2 Global Animal Stem Cell Therapy Market Share Forecast by Type (2020-2024) 5.4 Animal Stem Cell Therapy Market Forecast by Application (2020-2024) 5.4.1 Global Animal Stem Cell Therapy Sales Forecast by Application (2020-2024) 5.4.2 Global Animal Stem Cell Therapy Market Share Forecast by Application (2020-2024)

6.Sales Channel, Distributors, Traders and Dealers 6.1 Sales Channel 6.1.1 Direct Marketing 6.1.2 Indirect Marketing 6.1.3 Marketing Channel Future Trend 6.2 Distributors, Traders and Dealers

7.Research Findings and Conclusion

8.Appendix 8.1 Methodology 8.2 Data Source

Continued..

Purchase this report (Price3480 USD for a single-user license) https://www.360researchreports.com/purchase/13837427

About Us:

360 Research Reports is the credible source for gaining the market reports that will provide you with the lead your business needs. At 360 Research Reports, our objective is providing a platform for many top-notch market research firms worldwide to publish their research reports, as well as helping the decision makers in finding most suitable market research solutions under one roof. Our aim is to provide the best solution that matches the exact customer requirements. This drives us to provide you with custom or syndicated research reports.

Contact Us: Name: Mr. Ajay More Email: [emailprotected] Organization: 360 Research Reports Phone: +44 20 3239 8187/ +14242530807

For More Related Reports Click Here :

Smart Airport Solutions Market 2020 : Global Industry Analysis by Top Countries Data, Potential Growth, Key Players, Latest Trends and Forecast to 2026

Aviation MRO Software Market Size 2020 Growing Rapidly with Latest Trends, Market Size with Top Countries Data, Investment Opportunities, Share, Revenue, Demand and Forecast to 2026

Materials Need in 5G Market 2020 : Top Countries Data, Industry Analysis, Size, Share, Growth, Trends, and Forecast to 2026

More here:
Animal Stem Cell Therapy Market 2020 with Top Countries Data : Market Size, Growth, Segments, Revenue, Top Manufacturers and Forecast to 2024 -...

Editorial: UT Health’s new teaching hospital will boost region – Laredo Morning Times

Express-News Editorial Board

Dr. William L. Henrich, president of UT Health San Antonio, said a new teaching hospital will complement what is currently offered at University Hospital.

Dr. William L. Henrich, president of UT Health San Antonio, said a new teaching hospital will complement what is currently offered at University Hospital.

Dr. William L. Henrich, president of UT Health San Antonio, said a new teaching hospital will complement what is currently offered at University Hospital.

Dr. William L. Henrich, president of UT Health San Antonio, said a new teaching hospital will complement what is currently offered at University Hospital.

Editorial: UT Healths new teaching hospital will boost region

A planned 144-bed teaching hospital on the UT Health San Antonio campus slated to open in the spring of 2024 will boost enrollment for many health programs so crucial for the region and state.

The medical school alone could see an increase of 22 students in each enrollment class. The number of medical residents could grow by 100 to 130 slots by 2027. Currently, 1,000 residency slots are offered through UT Health San Antonio.

This is great news for medical and other students training for health professions who want to complete their education in Texas. It will help address the shortage of providers in Bexar County and across the state. Historically, many doctors remain in the communities where they complete their medical training.

The San Antonio hospital would become the fourth operated by the University of Texas System. The others are in Dallas, Galveston and Tyler.

Most of the UT System health science centers have partnerships with independently managed hospitals in their communities.

Most new hospital projects arrive with much fanfare. This project has been quietly moving along over the past year with little public awareness or discussion.

The University of Texas System regents last month placed the nearly $400 million project on its capital improvement program and are expected to appropriate construction funds at their November meeting.

The hospital will be located on 12 acres in the South Texas Medical Center provided by the San Antonio Medical Foundation. The eight-story hospital will be adjacent to the Mays Cancer Center, formerly known as the Cancer Therapy and Research Center. The jointly run UT Health San Antonio-MD Anderson program is a National Cancer Institute-designated research center. The hospital and the cancer center will be connected by a skybridge.

A 530-space parking garage is also included in the project.

Background information provided to the regents describes a high-acuity hospital offering treatment programs in cancer, neurosciences, orthopedics, urology, thoracic surgery and bariatrics.

A distinct, competitive advantage of the hospital will be the unique leading-edge therapies and early-phase clinical trials in the many disciplines in which the university has expertise, including immunologic and stem cell therapies in oncology and diabetes, the backgrounder states.

The construction of a second teaching hospital in San Antonio raises concerns about the multibillion-dollar investment taxpayers have made in the Bexar County Hospital District, which includes University Hospital and some two dozen University Health System clinics.

University Hospital has long been the primary teaching hospital for UT Health San Antonio, and much of its recent expansion including the new 400-bed Womens and Childrens Hospital now under construction alongside University Hospital has been in large part to accommodate the patients seen by UT Health San Antonio doctors.

Will the two be duplicating services and competing for patients?

UT Health San Antonio President William L. Henrich and Bexar County Judge Nelson Wolff said the two hospitals will work in partnership. The hospital district and UT officials are negotiating a memorandum of understanding to that effect, Wolff said.

Henrich said the new hospital will not replicate any services and will complement what is currently offered. He said the new facility will allow for the expansion of the health science centers three primary missions clinical care, biomedical research and education.

Our clinical practices have been growing 8 to 10 percent a year, Henrich said. We have about $300 million in research on campus, and we need more access to clinical trials. Sophisticated clinical trials in cancer, rheumatology, gastroenterology and this hospital will afford us the opportunity to carry out those trials, and that will be a unique feature of this hospital.

In addition, the new hospital is expected to create 750 to 850 new jobs.

This is an important project for San Antonio and Texas. It will expand higher education opportunities, help address the doctor shortage in the state and provide a lift to the local economy by creating skilled jobs.

We look forward to a thriving partnership between UT Health and the University Health System.

Continued here:
Editorial: UT Health's new teaching hospital will boost region - Laredo Morning Times

Mum’s message to the complete stranger who saved her son’s life – LincolnshireLive

A mum says the surprise baby she feared she would lose because of a rare genetic disorder is now living a normal life thanks to a bone marrow transplant from a complete stranger.

Former clinical psychologist Zoe Alderson has told how her son Henry was diagnosed with a rare genetic disorder, affecting just 125 people in the UK meaning he needed monthly blood transfusions.

But everything changed in April 2019 when Henry who has Diamond Blackfan Anaemia (DBA), which is caused by the bone marrow failing to produce red blood cells received a successful bone marrow transplant.

Zoe, 33, of Harwich, Essex, said he went from relying on transfusions to stay alive to having the blood count of a normal child his age, adding: We have no idea who provided the bone marrow, but not a day goes by when we dont think about that person. We will be forever in their debt.

At one point, it felt like we would never have a normal life, now you cant tell Henry apart from any other happy four-year-old.

Zoes own health problems began with fatigue, headaches and irregular periods throughout her teens.

But, in 2004, when she saw her doctor after her breasts began lactating, a blood test revealed she had higher than normal levels of the hormone prolactin. Amongst other things, it encourages the growth of breasts and lactation during pregnancy.

I didnt have a clue what was wrong with me, she explained.

I wrote it off as being stressed and nothing more.

Referred to Colchester Hospital in Essex in November 2004, an MRI scan revealed she had a benign 1cm tumour on her pituitary gland, at the base of her brain and was put on a prolactin inhibitor which she still takes to this day and, within six months, the tumour shrank to 3mm.

Doctors told me it was classed as a brain tumour, but I didnt need to panic, she continued. They said I might face some difficulty getting pregnant, though.

My periods were so irregular afterwards, that I never expected to conceive.

I wasnt that bothered, either, as I was just happy to be told the tumour was benign.

Meeting her husband Craig, 40, a graphic design company manager, at a work Christmas do in December 2007, within a year they moved in together.

But, firmly on a career path, they flew to Mombasa, Kenya, for an intimate wedding with their nearest and dearest on March 17, 2010 and thoughts of having children could not have been further from their minds.

Zoe said: We really werent fussed, or thats what we told ourselves.

She continued: We were both career driven and in our prime. Wed never even discussed the possibility of IVF or adoption it just wasnt on the radar.

But all that changed in January 2015, when Zoe was plagued with morning sickness.

I hadnt had a period for years, she said.

But Id been sick for a solid few days.

She continued: At first, I dismissed it as a bug, but when it lasted over a week, I thought I should do a pregnancy test before I saw a doctor.

I picked one up from the supermarket and when it came back positive, I just sat in the bathroom having a bit of a cry.

It was such a shock, it was just crazy.

She continued: Craig was absolutely thrilled, though, for someone who had said he wasnt fussed about having a baby.

But soon Zoe was haunted by the feeling that something wasnt right, with the pregnancy.

Then, at the 12-week scan, in early April 2015, the couple were told their baby showed signs of a genetic defect and was unlikely to survive to full-term, after finding a worrying amount of fluid around his head which is often an indicator of chromosomal defects in a foetus, according to the NHS.

Zoe said: Craig, ever the optimist, was convinced wed walk in and everything would be fine and dandy.

But moments after finding the heartbeat, the womans face dropped and before I knew it there were five medics huddled around the screen looking at the scan.

We were asked to wait down the corridor where doctors explained there was a high chance the baby had a genetic defect and was unlikely to survive for two more weeks.

Given chorionic villus sampling (CVS) a prenatal test to detect birth defects after three days the results came back negative for the most common conditions, but further testing for rarer defects left the expectant parents playing an agonising waiting game.

It felt like we had already written off our baby at that point, said Zoe.

We were carrying out the testing as an insurance policy, to see if there was a chance we could pass on any faulty genes in the future.

She continued: We were offered a termination but decided to let nature take its course.

And nature clearly had a positive plan for their baby boy, who continued to grow at a healthy rate.

We hit 14 weeks, then 20, then 24 and somehow we even made it to 36 weeks, Zoe said.

She continued: We still didnt have the results back from the genetic screening, but making it so far surprised everyone.

The consultant was amazed, he said hed never seen such a poorly foetus survive to this point.

But, just days after the milestone scan, Zoe could not feel the baby moving and rushed to Colchester Hospital, where a scan showed he was in distress.

Concerned, doctors performed an emergency C-section, delivering baby Henry on November 20, 2015.

When Henry was born we didnt know what was wrong with him still, said Zoe.

He let out a cry, but was ghostly white and was rushed to neonatal intensive care.

His pale complexion meant doctors assumed Henry had suffered from a placental haemorrhage in the womb, with a blood test showing he had a low red blood cell count.

Placed in an induced coma, the tot spent three weeks in intensive care, receiving three blood transfusions, to build up his red blood count.

I didnt get to see him on the day he was born, Zoe recalled. But I sent Craig down right away to keep an eye on him.

She continued: After the blood transfusions, he looked like a proper baby again and I couldnt wait to get him home.

Discharged at the beginning of December, the new parents were told to bring Henry in at the first sign of anything unusual.

He screamed around the clock and would not take to the bottle, but it was only when Henry turned deathly pale, on Christmas Eve, that the couple rushed him back to the hospital, where further tests revealed his red blood cell count was dangerously low leading to another transfusion.

For the next three months, every month, the couple would return to the hospital for Henry to receive a blood transfusion until, at four months old, he had a bone marrow biopsy.

Up until that point, all they could tell us was that Henry was anaemic, but that they didnt know why, Zoe explained.

The consultant examined the biopsy straight away and said it looked like he had DBA.

She continued: It was the first time wed heard of it, but as soon as we got home and Googled it, wed basically diagnosed Henry ourselves.

Two months later, by then six months old, his CVS results made the diagnosis official.

And, from then onwards, little Henry needed a blood transfusion every month with doctors telling his parents this would continue for the rest of his life.

Zoe said: It felt like Groundhog Day. After the transfusion hed be full of energy and behaving like a normal child.

But slowly, as the days passed, you could literally see the life draining out of him.

It sounds awful, but by the end of the month he really did look dead.

When he reach 18 months old, the couple were told Henrys body was suffering from an iron overload, because of his numerous blood transfusions.

To avoid iron poisoning which can cause severe damage to major organs he began taking iron chelation drugs, to remove the excess mineral from his body.

Administered through an IV, which Henry was hooked up to every night, Zoe said: It was such a difficult period for us.

She continued: It was bad enough seeing him deteriorate each week, without having to start sticking a needle into him every night as well.

He hated it at the time, but was fine during the day. Looking back, he was remarkably brave.

But when Zoe was told in February 2019 that he would need to be hooked up to the iron chelation machine 24 hours a day, she put her foot down.

Thats when I drew the line, she said. It wasnt fair expecting that of a child and I said I wanted them to look into alternatives.

Thats when doctors said Henry would be eligible for a bone marrow transplant.

After that, by then aged three, things moved quickly and, just six weeks later, Henry was matched with a tissue donor.

Then, in the last week of April 2019, he had chemotherapy to wipe out his existing bone marrow, before having a central line fitted, allowing the new stem cells to pass through his blood stream.

Put on immunosuppressants a type of medicine which stop the body from rejecting donor tissue for 12 months, Zoe said she witnessed a miracle, as she slowly got her boy back.

He hasnt needed a blood transfusion since he had the bone marrow donation, she said. Hes a completely different child.

She continued: Hes full of energy around the clock now not just for a few days a month.

I dont think we realised just how poorly he had been for the last four years until he recovered. That had become our normal.

Taken off immunosuppressants in May 2020, a month later, blood tests revealed that Henry had the blood count of an average four-year-old.

For his whole life hes been in and out of hospital and now, finally, he can start to live like any other kid, said Zoe.

Ringing the end of treatment bell was such a big deal for all of us.

It felt like the end of that chapter in our lives.

Desperate to raise awareness of DBA and the importance of bone marrow donation, Zoe now has an important message she wants to send to whoever saved her sons life.

Were so grateful to whoever it was that donated their bone marrow for Henry, she said.

To anyone else out there who isnt on the donor register, please sign up.

She continued: All it takes is a bit of your spit sent in the post and it could quite literally save someones life.

Go here to read the rest:
Mum's message to the complete stranger who saved her son's life - LincolnshireLive

Important to balance benefits of cancer-related care with risks related to COVID-19: Dr Hari Menon – Express Healthcare

While explaining how healthcare organisations have reinvented and adapted to the new normal to ensure that citizens get definitive cancer care during the COVID-19 crisis, Dr Hari Menon, senior consultant, haemato-oncology, Cytecare Cancer Hospitalcautions that demographic changes alone will cause cancer cases to double over next two decades in India and therefore suggests three top measures that can accelerate the countrys fight against cancer, in an interaction with Viveka Roychowdhury

How has the COVID-19 pandemic impacted access to cancer care in India?

The pandemic has altered every aspect of life worldwide. Understandably, the impact on access to cancer care in India was unavoidable especially during the initial lockdown. However, over the last couple of months, healthcare organisations have reinvented and adapted to the new normal to ensure that citizens get definitive cancer care during the crisis.

Its important to balance the benefits of cancer-related care with the risks related to COVID-19. At Cytecare, our primary concern has been to ensure that patients continue their treatment while alleviating their concerns about compromised immunity leading to infection. Here are a few measures that we took:

What is Indias burden of cancer cases and how is it projected to increase in the next five years?

According to the National Cancer Registry Programme Report, 2020, there are 1.39 million cancer cases in India currently. By 2025, the number is estimated to reach 1.57 million.

The report, released recently by the Indian Council of Medical Research (ICMR), finds that tobacco-related cancer contributes to 27.1 per cent of the total cancer burden about 370,000 cases in 2020.

It is expected that demographic changes alone will cause the number of cancer cases to double over the next two decades. Currently, non-communicable disease is the second leading cause of adult death in urban India and fourth leading mortality cause in rural India.

What are the most prevalent cancers in India and do we have an epidemiological study of cancers to prevent them or lessen incidence in the next generation?

The term cancer refers not just to one disease, but a collection of several diseases, with wide-ranging characteristics that usually call for varied treatments. In India, cancers of the lung, mouth, stomach, prostate cancer and oesophagus are the most prevalent among men, while breast and cervical cancer rank the highest in terms of prevalence among women.

The National Cancer Registry Programmes Report, 2020, notes that cancers of the gastrointestinal tract (in men and women) account for about 19 per cent of the countrys cancer burden. The report also states that the incidence of breast cancer is rising, while cervical cancer is declining.

Another insightful study published in The Lancet Oncology last year had stated that cervical cancer could be potentially eliminated as a public health problem in India within the next 60 years given the promise shown by the vaccination programme against human papilloma virus (HPV) and cervical screening made more accessible.

Better and early diagnosis of cancer through screening and awareness campaigns has improved the chances of survival and quality of life. To what extent?

Early detection with specified treatment protocols is critical for better long term outcomes. Delay in diagnosis can lead to compromised outcomes to treatment. In fact, it also means giving more aggressive treatment inviting complications and impinging quality of life. A delay in detection will consecutively cause the cancer cells to spread in the adjacent areas of the affected region, thus increasing the morbidity. Also, in the absence of early detection and simultaneous treatment, the patients cancer-related disability increases, thereby dipping the chances of survival.

We have observed that early detection is particularly true for superficial cancers such as breast, head and neck and cervical cancers among others. We need to spread more awareness about the importance of screening programmes and invest in diagnostic facilities at local healthcare centers across the country.

Also, the five-year survival rate increases significantly when the cancer is detected at an early stage I or II, as compared to the more advanced stage III or IV tumours. Given the socio-economic inequalities in access to healthcare and the high out-of-pocket expenditure in India, these are important factors to consider.

It is a perceived notion that cancer afflicts the Indian population about a decade younger than their western counterparts. However, this may not be entirely true given that the older population are less inclined to come forward for treatment and may present at more advanced stage as compared to younger population. Therefore early diagnosis and treatment becomes all the more significant.

Are cancer care facilities, from screening, diagnosis, and treatment, accessible and affordable to all patients in India? Especially in rural areas? How successful have government schemes like Ayushman Bharat been while addressing these issues?

Theres no denying that India is grappling with inadequate infrastructure and poor access to healthcare. The country has merely 0.98 oncologists per million population.

It is also true that cancer treatments can be expensive most of the time because the treatment involves a comprehensive approach involving not only the management of the patient and his well-being but also supportive care management of disabilities that might be temporary or permanent and the need to get them back to main stream after a curative treatment has been implemented.

As the worlds largest fully government-financed health insurance scheme, Ayushman Bharat could be the game changer. Right now, there are about 150 oncology packages that cater to patients from economically disadvantaged sections of the society. Once Health and Wellness Centres (HWCs) under Ayushman Bharat succeed in screening effectively for cancers, detection and timely treatment can become a reality for the 1.3 billion population.

There are three top measures that can accelerate Indias fight against cancer:

How has the National Cancer Grid worked to solve these issues? In terms of teleconsultation, reference network etc?

At a conceptual level, the National Cancer Grid represents a collaborative approach for addressing cancer at the national level. By bringing together institutions both in public and private sector under one roof, it can ensure uniformity in protocols and implementation of cancer care and treatment. The potential is immense and there is a lot of promise for this umbrella organisation to implement definitive therapy for cancer patients, while also addressing methods to improve cancer care in the future

What is the future of cancer care in India, at institutions like Cytecare Cancer Hospital? In terms of expansion and investment plans to reach more patients, cover more types of cancers, offer the latest treatment options in cancer care in India?

We know a lot more about this complex disease today than we did a decade or two ago, thanks to cutting-edge cancer research that is being conducted across the globe. Right from prevention and early detection to treatment of late-stage disease, there are several encouraging developments.

Diagnostic scans are getting more accurate and radiation treatments come with lesser side effects today. The development of immunohistochemistry (IHC), markers for various cancers, liquid biopsies and genetic tests have transformed the way we diagnose and tailor cancer treatments. Similarly, the development of newer drugs for targeted treatment and breakthroughs in stem cell research and gene therapy are paving the way for effective and personalised cancer care in the future.

At Cytecare, we are committed to building a more patient-centric cancer care system, with an organ-site approach. Our endeavour, since our inception in 2016, has been to get the finest multidisciplinary team of clinicians to work together with a holistic approach. Currently, we have a world-class team of 22 cancer specialists the largest such team in India that understands and evaluates each patients unique journey.

Read more here:
Important to balance benefits of cancer-related care with risks related to COVID-19: Dr Hari Menon - Express Healthcare

Wexner Medical Center performs gene therapy brain infusion for Parkinson’s disease – The Highland County Press

For the first time ever, a team of neurologists and neurosurgeons atThe Ohio State University Wexner Medical CenterandThe Ohio State College of Medicinehas performed a novel gene therapy brain infusion to treat a patient with Parkinsons disease.

This multicenter, Phase 1bclinical safety studyis sponsored byBrain Neurotherapy Bio, Inc.and funded by theCalifornia Institute for Regenerative Medicineto test GDNF gene therapy in patients with early to moderate stages of Parkinsons disease. The one-time treatment involves infusion of a gene therapy solution into deep structures of the brain that are affected by the disease.

Parkinsons disease is a neurodegenerative movement disorder that affects one million people in the United States. Degeneration of neural pathways deep in the brain causes symptoms such as tremor, slow movement and behavioral abnormalities, said Ohio State neurosurgeon Dr. James Brad Elder who performed the gene therapy surgery on Aug. 25.

The overall goal of this gene therapy treatment strategy is to slow the neurologic deterioration associated with Parkinsons disease by enhancing levels of a naturally occurring growth factor called GDNF. Targeting gene therapy delivery to the putamen, a deep brain structure affected by Parkinsons disease, will hopefully improve overall quality of life, Elder said.

The patient, a 55-year-old Ohio man first diagnosed with Parkinsons disease in 2008, takes medicine to help control his progressively worsening disease. He said the gene therapy surgery gives him hope that his disease wont get any worse, and that he may even feel better without medications. But he added that it could take up to six months before he notices any improvements.

There has long been evidence in animal and cell culture models of Parkinson's disease suggesting that glia cell derived neurotrophic factor (GDNF) has promise as a therapy for the disease, said Dr. Sandra Kostyk, director of theMovement Disorders Divisionat Ohio State Wexner Medical Center. Patients with Parkinsons disease and related disorders are diagnosed and treated in the Movement Disorders clinics and neurosurgery programs at Ohio State.

One of the biggest clinical hurdles has been getting the molecule to the regions in the brain that would benefit these patients the most. GDNF is a relatively large molecule that cant be administered as a pill, nor intravenously, since it cant penetrate the blood brain barrier.

This new targeted gene delivery approach overcomes many of the obstacles that have slowed GDNF clinical trial research and is expected to facilitate the production of a continuous supply of GDNF to a critical region of the brain affected by Parkinsons disease.

This is a onetime treatment strategy that could have ongoing lifelong benefits. Though its hoped that this treatment will slow disease progression, we dont expect this strategy to completely stop or cure all aspects of the disease.Were cautiously optimistic as this research effort moves forward, Kostyk said.

Brain Neurotherapy Bio is a biotechnology startup company founded in 2018 byDr. Krystof Bankiewiczto develop gene therapies for neurological disorders. Bankiewicz is also a member of Ohio State Wexner Medical CentersNeurological Institute.

Ive been investigating therapeutic gene therapy approaches for Parkinsons disease for nearly 30 years, and this marks a significant milestone that may lead to major therapeutic opportunities for those suffering with this devastating condition, said Bankiewicz, who is CEO and chairman of the board of Brain Neurotherapy Bio.

Additional sites for this clinical trial include the University of California San Francisco and the University of California Irvine medical centers. For more information, emailOSUgenetherapyresearch@osumc.edu.

See the original post here:
Wexner Medical Center performs gene therapy brain infusion for Parkinson's disease - The Highland County Press

Pharmaceutical and Biotechnology Machines Market: How the Business Will Grow in 2027? – The News Brok

The Pharmaceutical and Biotechnology Machines Market Analysis to 2027 is a specialized and in-depth study of the medical device industry with a special focus on the global market trend analysis. The report aims to provide an overview of pharmaceutical and biotechnology machines market with detailed market segmentation by of product and end user/application. The pharmaceutical and biotechnology machines market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading players in pharmaceutical and biotechnology machines market and offers key trends and opportunities in the market.

Some of the key players profiled in the study areAir Liquide, Atlas Copco AB, Beijing Orient, Linde Healthcare, Messer Group, Nanning Lantian, Shenwei Medical, Shenzhen Gaofa, Sicgil India Limited, SOL Group, Taiyo Nippon Sanso, etc.

To get sample Copy of the report, along with the TOC, Statistics, and Tables please visit @ https://www.theinsightpartners.com/sample/TIPRE00011795/

What is Pharmaceutical and Biotechnology Machines Market?

The biotechnology machine is for process Separations. Also, process-scale separation systems, mainly high-volume chromatography systems, are among the most crucial biotechnology machine in the modern biopharmaceutical industry. Its applications of process chromatography include recombinant protein purification. Pharmaceutical biotechnology refers to the use of biotechnology for manufacturing drugs, gene therapy as well as gene testing. This is done by manipulating and modifying organisms, usually at the molecular level.

The pharmaceutical and biotechnology machines market is propelling due to advancement of technology and rising geriatric population. However, the high cost of devices, stringent regulations, and lack of skilled personnel hamper the market growth.

The pharmaceutical and biotechnology machines market is segmented on the basis of product and end user/application. Based on product, the market is segmented as oxygen, nitrous oxide, medical air and others(nitrogen, carbon dioxide and helium). On the basis of end user/application, the market is categorized as hospitals (labs and clinics), home healthcare, universities/research institutions and pharmaceutical and biotechnology industries.

!!! Limited Time DISCOUNT Available!!! Get Your Copy at Discounted [emailprotected] https://www.theinsightpartners.com/discount/TIPRE00011795/

Key questions answered by this report:

Our reports will help clients solve the following issues:

Insecurity about the future:

Our research and insights help our clients anticipate upcoming revenue compartments and growth ranges. This will help our clients invest or divest their assets.

Understanding market opinions:

It is extremely vital to have an impartial understanding of market opinions for a strategy. Our insights provide a keen view on the market sentiment. We keep this reconnaissance by engaging with Key Opinion Leaders of a value chain of each industry we track.

Understanding the most reliable investment centers:

Our research ranks investment centers of market by considering their future demands, returns, and profit margins. Our clients can focus on most prominent investment centers by procuring our market research.

Evaluating potential business partners:

Our research and insights help our clients identify compatible business partners.

Interested in purchasing this Report? Click here @ https://www.theinsightpartners.com/buy/TIPRE00011795/

Pharmaceutical and Biotechnology Machines Market Segmented by Region/Country: North America, Europe, Asia Pacific, Middle East & Africa, and Central & South America

About Us:

The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are committed to provide highest quality research and consulting services to our customers. We help our clients understand the key market trends, identify opportunities, and make informed decisions with our market research offerings at an affordable cost.

We understand syndicated reports may not meet precise research requirements of all our clients. We offer our clients multiple ways to customize research as per their specific needs and budget

Contact Us:

The Insight Partners,

Phone: +1-646-491-9876

Email: [emailprotected]

Go here to read the rest:
Pharmaceutical and Biotechnology Machines Market: How the Business Will Grow in 2027? - The News Brok

Clinics ‘peddling false hope for autism with potentially hazardous 14,000 cell therapy’ – Mirror Online

Clinics have been accused of peddling false hope to parents of autistic children with potentially hazardous treatment.

A Sunday People probe found dozens of private firms charging up to 14,000 for stem cell therapy, claiming it provides a whole range of benefits.

Clinics insist the treatment in which donor cells are fed into a patients bloodstream via a drip can help improve youngsters social skills, speech and concentration.

But there are counter-claims that the therapy is unproven, could be distressing for children and even cause them more harm than good.

One mum blasted adverts for it as horrifying while other parents who forked out huge sums of cash complained it had little effect.

One called the therapy a 99 per cent failure and another said: I spent a ton of money on my two kids and nothing happened.

Professor Richard Mills, consultant for non-profit AT-Autism, said: Stem cell therapy is regarded within the medical community as potentially quite hazardous and there isnt so far a reliable evidence base that would cause it to be recommended.

It is controversial and experimental and Im not aware of any independent studies which prove it works.

Prof Mills said parents should see the high costs, the absence of regulated independent trials and testimonials as red flags of caution.

He added there were also huge ethical issues linked to treating children who may lack the capacity to consent to it.

He said: Using an intravenous injection, an infusion of fluid goes into the brain, which is unpleasant at best and may be highly distressing and traumatic for an autistic child.

One in every 100 kids in the UK has some form of autism, for which there is no medical cure.

The clinics we found work on the disputed premise that autism is a neurological disorder with clear causes that can be altered by intervention.

Most say stem cells, which can develop into other types of bodily cells and renew themselves, will have a reparative effect on the brain.

Stem cells are approved for treating some blood conditions, skin grafts and cornea repairs but remain unproven in regard to autism.

Only after full clinical trials can procedures be declared safe and better than existing treatments.

Prof Mills went on: These practitioners attempt to interfere with the core symptoms of autism, as they put it, but the National Institute for Health and Care Excellence has said there are no proven ways of altering this.

The Autism Regenerative Centre in Marylebone, central London, claims to have given therapy to over 500 children since 2014 without complications and says 80 per cent of them showed improvement.

An online ad for the private clinic says its treatments pass beyond the limitations of conventional therapies. We found further clinics around the world advertising in English and welcoming patients of all nationalities.

Swiss Medica features an online testimonial from a British family whose autistic child was treated at its premises in Goldach, Switzerland.

The online clip shows Paul from Reading saying the treatment in the UK is not what we liked for his three-year-old autistic son, but that the family were now feeling more optimistic.

The Swiss clinics website claims conventional treatment methods for autism only smooth out the specific symptoms, targeting one or two of them, whereas stem cell therapy is an entirely new tool.

The Stem Cell Institute in Panama charges between 10,000 and 13,000 for four-day packages for children.

It says the therapy decreases inflammation in the brain which may alleviate autism symptoms.

German International Clinic in Frankfurt charges more than 14,000 for the procedure, which it says will be effective for just three to eight months and recommends follow-up sessions.

It lists improved communication ability and memory as benefits.

But Brit mum Emma Dalmayne, whose children Damien, 12, and Skylar, seven, are autistic, was disgusted by the ads.

Emma, 44, who is autistic herself and runs the Autistic Inclusive Meets group, said: Its horrifying that parents of vulnerable children are being presented with a medical procedure thats not scientifically proven.

There has to be regulation to stop this. Emma, of Woolwich, south-east London, begged families to invest in occupational and speech therapies instead.

She warned: If you go down the pseudo-science route, youll be encouraged to part with huge sums of money that could otherwise go towards a proven therapy.

One US mum who spent 30,000 on treatment for her two kids in Mexico with no results said she believed stem cell therapy was a scam.

The woman, a 52-year-old nurse from New York who took out loans to fund the treatment, was taken in by online testimonials.

But she said: Nothing happened, nothing at all. Its a money-maker there are a lot of desperate people out there.The National Autistic Society accused firms of exploiting parents.

Director of external affairs Jane Harris said she was not aware of any stem cell trials for autism, and added: Private companies are taking advantage of autistic people and their families, asking them to pay for unproven and even dangerous treatments.

Dr Jon Goldin, vice chair of the Child and Adolescent faculty at the Royal College of Psychiatrists, said: There is currently no known cure for autism nor is there any scientific evidence that stem cells can be used safely and effectively as a treatment.

Labour MP Jonathan Reynolds, vice chair of the All Party Parliamentary Group on autism and father of an autistic son, said: It is incredibly worrying to hear that people might be being exploited when they are in such a vulnerable position.

Go here to read the rest:
Clinics 'peddling false hope for autism with potentially hazardous 14,000 cell therapy' - Mirror Online